Nature of Business (Details) (USD $)	0 Months Ended			12 Months Ended				0 Months Ended	12 Months Ended
	Oct. 15, 2013	Oct. 23, 2012	Aug. 01, 2011	Dec. 31, 2013 Program	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Feb. 05, 2014 Subsequent Event [Member]	Dec. 31, 2013 Aldoxorubicin [Member]	Dec. 31, 2013 Albumin-Binding Cancer Drugs [Member]	Dec. 31, 2013 General Operation [Member]	Dec. 31, 2013 Other General and Administrative Expenses [Member]
Nature of Business [Abstract]
Number of programs in clinical development for cancer indications				2
Estimated Projected Expenditure Type [Line Items]
Cash and cash equivalents				$ 11,483,112	$ 14,344,088	$ 17,988,590	$ 6,324,430
Marketable securities				27,084,980	24,000,000
Net proceeds from common stock issued in public offering	24,100,000	21,500,000	18,900,000	24,094,530	21,476,815	18,939,619		80,500,000
Projected expenditures for clinical programs				$ 39,900,000					$ 28,000,000	$ 1,500,000	$ 3,100,000	$ 7,300,000